Invivyd, Inc.

NASDAQ:IVVD

Biotechnology

Healthcare
$0.47 +4.16%

+$0.04 today

Market cap
$138.68M
Beta
0.63
P/E (TTM)
-3.9
EPS (TTM)
-$0.25
52W Low $0.48High $3.07

Volume 6.71M

Average 3.62M

IVVD Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Invivyd, Inc.NASDAQ: IVVD

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin narrows to 88.8%

Gross margin was 88.8% in Q1 FY2026, down 3.9 pp from a year earlier. On a trailing-twelve-month basis it was 92.0%, down 1.3 pp year over year.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
88.8%-4.6 pp QoQ
Last fiscal yearDec 2025
93.0%-0.6 pp YoY
LTMMar 2026
92.0%-1.3 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-3.9 pp——
1 year-0.6 pp——
3 years———
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
93.0%
Year-over-year change
-0.6pp

Gross Margin vs competitors

How IVVD compares with its peers on the latest reported figures

  • IVVD's LTM Mar 2026 gross margin of 92.0% is the 5th highest of the 8 companies compared; the peer median is 94.8%.
  • Its year-over-year change of -1.3 pp is the 5th highest of 7, against a peer median of +3.3 pp.
IVVD Competitors Peer median
Gross Margin for IVVD and competitors
Company Period LTM level YoY 3-year change
NTHINeonc Technologies Holdings, Inc.FY2025100.0% ——
SGMOSangamo Therapeutics, Inc.LTM Mar 2026100.0% +0.0 pp-8.3 pp
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 202699.3% +6.7 pp+8.5 pp
CCCCC4 Therapeutics, Inc.LTM Mar 202694.8% +9.6 pp-22.2 pp
IVVDInvivyd, Inc.LTM Mar 202692.0% -1.3 pp—
CDXSCodexis, Inc.LTM Mar 202683.9% +12.4 pp+14.2 pp
OABIOmniAb, Inc.LTM Mar 202635.5% -64.5 pp-118.2 pp
IMDXInsight Molecular Diagnostics Inc.LTM Mar 202619.5% -33.1 pp+6.6 pp
SLSSELLAS Life Sciences Group, Inc.FY2025— ——
TARAProtara Therapeutics, Inc.FY2025— ——
Peer median (excluding IVVD) 94.8%+3.3 pp-0.9 pp

Competitors are the stored peer set for IVVD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00025.38M53.43M
Cost of Revenue0001.62M3.75M
Gross Profit00023.77M49.68M
Gross Margin———93.6%93.0%
Research & Development182.89M179.21M158.66M137.25M38.31M
Selling, General & Admin36.52M47.04M49.13M63.39M66.93M
Operating Expenses226.91M248.03M212.76M200.64M105.24M
Depreciation & Amortization1K462K2.03M3.11M2.11M
EBITDA(219.41M)(225.8M)(205.76M)(166.81M)(50.38M)
EBITDA Margin———-657.2%-94.3%
Operating Income(226.91M)(248.03M)(212.76M)(176.88M)(55.56M)
Operating Margin———-696.8%-104.0%
Interest Income06.71M06.95M0
Interest Expense043.08M000
Other Income / Expenses118K6.71M14.12M6.95M3.07M
Income Before Tax(226.79M)(241.32M)(198.64M)(169.93M)(52.49M)
Pre-Tax Margin———-669.4%-98.2%
Income Tax Expense00000
Net Income(226.79M)(241.32M)(198.64M)(169.93M)(52.49M)
Net Margin———-669.4%-98.2%
EPS (Basic)(2.11)(2.17)(1.81)(1.43)(0.30)
EPS (Diluted)(2.11)(2.17)(1.81)(1.43)(0.30)
Weighted Avg Shares110.78M108.27M109.53M118.56M172.21M
Weighted Avg Shares (Diluted)110.78M108.27M109.53M118.56M172.21M

Invivyd, Inc.

NASDAQ:IVVD

Intrinsic Alpha fair value

Locked

Current Price

$0.47

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.